JP Morgan Chase’s Contineum Therapeutics CTNM Stock Holding History

JP Morgan Chase’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	13,481 +10,993	+442%	+$144K	﹤0.01%	5610
2026 Q1	$31K	Buy	2,488 +696	+39%	+$9.34K	﹤0.01%	6379
2025 Q4	$20.5K	Buy	+1,792	New	+$20.4K	﹤0.01%	6496
2025 Q3	–	Sell	-1,108	Closed	-$4.4K	–	7779
2025 Q2	$4.4K	Sell	1,108 -4,059	-79%	-$17.6K	﹤0.01%	6432
2025 Q1	$36.1K	Sell	5,167 -23,259	-82%	-$212K	﹤0.01%	5977
2024 Q4	$416K	Buy	28,426 +25,934	+1,041%	+$411K	﹤0.01%	5139
2024 Q3	$47.7K	Sell	2,492 -466	-16%	-$8.94K	﹤0.01%	6009
2024 Q2	$52.1K	Buy	+2,958	New	+$47.6K	﹤0.01%	5843

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's CTNM Position: Q2 2026 in Review

JP Morgan Chase increased its Contineum Therapeutics (CTNM) stake by 442% in Q2 2026, buying an estimated $144K and bringing the position to 13,481 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #5610.

JP Morgan Chase first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $416K in Q4 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

JP Morgan Chase held 13,481 shares of Contineum Therapeutics worth $202K as of Q2 2026.
JP Morgan Chase bought 10,993 Contineum Therapeutics shares in Q2 2026, an estimated $144K.
Contineum Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5610 holding.
JP Morgan Chase first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
JP Morgan Chase's Contineum Therapeutics position peaked at $416K in Q4 2024.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.